Drug shows promise for people with mild Alzheimer's
Two studies to test an experimental drug to treat mild cases of Alzheimer's seem to show that doctors are on the right track by trying to clear the sticky deposits that clog's patient's brains. The combined results from testing of the drug suggest it might modestly slow mental decline. Taken separately, the studies missed their main goal to significantly slow the mind-robbing disease. But pooled results show 34 percent less delcine in mild Alzheimer's patients compared to those on a placebo for 18 months. The drug is called solanezumab and is developed by Eli Lilly & Company.